Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The epidermal growth factor receptor (EGFR)3 is a 170 kD transmembrane tyrosine kinase activated by several ligands. It is required for normal mammary development and lactation and is aberrantly expressed in approximately 40% of breast carcinomas, particularly those with a poor prognostic phenotype. Since EGF receptor levels are elevated in a high proportion of many tumor types its potential as a therapy target is being investigated using the EGF receptor to target toxins, as well as drugs that interfere with signaling and anti-receptor antibodies. These approaches are likely to be most effective when used in the adjuvant situation in combination with chemotherapy.

Original publication

DOI

10.1023/a:1026399613946

Type

Journal article

Journal

J Mammary Gland Biol Neoplasia

Publication Date

04/1997

Volume

2

Pages

131 - 141

Keywords

Breast, Breast Neoplasms, ErbB Receptors, Female, Gene Expression Regulation, Neoplastic, Humans, Lactation, Ligands